SHERLOCK BIOSCIENCES, INC.

Sherlock Biosciences, Inc. specializes in the design and development of rapid, point-of-need molecular diagnostics for infectious disease detection, with a focus on low-cost, deployable platforms that enable self-collected specimen analysis. Their technical expertise lies in CRISPR-based nucleic acid detection systems, isothermal amplification technologies, and lateral flow readout architectures optimized for resource-limited settings. The company differentiates itself through innovations in assay sensitivity and specificity without requiring lab infrastructure, enabling accurate detection of pathogens such as influenza A and B directly from nasal swabs in field or home environments. Their work integrates synthetic biology, microfluidics, and diagnostic algorithm design to deliver deployable molecular testing solutions that bridge the gap between laboratory-grade accuracy and community-level accessibility. Sherlock Biosciences has demonstrated direct engagement with the Department of Health and Human Services, delivering research and development solutions aligned with public health preparedness priorities. The relationship centers on advancing diagnostic tools for infectious disease surveillance and response, particularly for respiratory pathogens requiring scalable, non-laboratory-based detection. This reflects a strategic alignment with HHS’s mission to enhance domestic biodefense and pandemic readiness through decentralized diagnostic capabilities. The company’s primary industry focus is research and development in biotechnology, specifically in the design of next-generation molecular diagnostics that move beyond traditional PCR-dependent platforms. Their vertical specialization is in infectious disease diagnostics, with an emphasis on point-of-care and point-of-need applications that prioritize speed, simplicity, and accessibility. This positions them at the intersection of synthetic biology innovation and public health infrastructure modernization. Sherlock Biosciences, Inc. is a privately held entity based in Watertown, Massachusetts, with no government certifications on record. Their geographic footprint is centered in the Boston biotech corridor, leveraging regional academic and biomanufacturing ecosystems to advance their diagnostic platforms for federal health security initiatives.